Clinical trial
The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5…
NCT00405015 · Radboud University Medical Center, Other · Completed
Key facts
| NCT number | NCT00405015 |
|---|---|
| Title | The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. |
| Official title | The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. A Double Blind Placebo- Controlled Cross-over Study in Subjects With the Metabolic Syndrome |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ischemia-Reperfusion Injury, The Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 13 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Nov 29, 2006 |
| Last update posted | Aug 24, 2010 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: